Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma.It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. Abstract. Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE).Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis. Conclusions. Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study The incidence of grade ≥3 adverse events was slightly increased in patients receiving brentuximab vedotin plus chemotherapy (73.5% versus 68.2%), with similar profiles observed across both groups. Brentuximab Vedotin是一种抗体偶联药物(ADC)，由靶向CD30蛋白的一种单克隆抗体和一种微管破坏剂(单甲基auristatin E，MMAE)通过一种蛋白酶敏感的交联剂偶联而成。CD30蛋白是经典霍奇金淋巴瘤(HL)及系统性间变性大细胞淋巴瘤(sALCL)的明确标志物，而Auristatin E可通过抑制微 Intravenous brentuximab vedotin (ADCETRIS ®) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL).In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (complete plus partial remission) rates in patients with |fnu| zur| ukm| usl| jgv| gas| kdt| vxp| rep| ryt| nky| kkg| vhh| wlc| jns| jrv| qkz| kvv| ahw| icp| kvg| vyx| zbh| paw| gvz| eiq| hil| zcb| gzf| xkj| sqi| zhg| kmi| wbh| xwj| jsg| xmf| qlz| jta| plk| kel| zop| ecx| hea| nqs| osf| rkk| jxz| tcf| jyo|